Rapid and rigorous IL-17A production by a distinct subpopulation of effector memory T lymphocytes constitutes a novel mechanism of toxic shock syndrome immunopathology by Szabo, Peter A. et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Public Health Resources Public Health Resources 
4-1-2017 
Rapid and rigorous IL-17A production by a distinct subpopulation 
of effector memory T lymphocytes constitutes a novel 
mechanism of toxic shock syndrome immunopathology 
Peter A. Szabo 
The University of Western Ontario 
Ankur Goswami 
The University of Western Ontario 
Delfina M. Mazzuca 
The University of Western Ontario 
Kyoungok Kim 
The University of Western Ontario 
David B. O'Gorman 
Hand and Upper Limb Centre 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.unl.edu/publichealthresources 
 Part of the Medical Sciences Commons, and the Public Health Commons 
Szabo, Peter A.; Goswami, Ankur; Mazzuca, Delfina M.; Kim, Kyoungok; O'Gorman, David B.; Hess, David 
A.; Welch, Ian D.; Young, Howard A.; Singh, Bhagirath; McCormick, John K.; and Haeryfar, S. M.Mansour, 
"Rapid and rigorous IL-17A production by a distinct subpopulation of effector memory T lymphocytes 
constitutes a novel mechanism of toxic shock syndrome immunopathology" (2017). Public Health 
Resources. 591. 
https://digitalcommons.unl.edu/publichealthresources/591 
This Article is brought to you for free and open access by the Public Health Resources at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Public Health Resources 
by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
Authors 
Peter A. Szabo, Ankur Goswami, Delfina M. Mazzuca, Kyoungok Kim, David B. O'Gorman, David A. Hess, 
Ian D. Welch, Howard A. Young, Bhagirath Singh, John K. McCormick, and S. M.Mansour Haeryfar 
This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
publichealthresources/591 
The Journal of Immunology
Rapid and Rigorous IL-17A Production by a Distinct
Subpopulation of Effector Memory T Lymphocytes
Constitutes a Novel Mechanism of Toxic Shock
Syndrome Immunopathology
Peter A. Szabo,* Ankur Goswami,* Delfina M. Mazzuca,* Kyoungok Kim,*
David B. O’Gorman,†,‡,x,{ David A. Hess,‖,# Ian D. Welch,** Howard A. Young,††
Bhagirath Singh,*,x,‡‡ John K. McCormick,*,x,‡‡ and S. M. Mansour Haeryfar*,x,‡‡,xx
Toxic shock syndrome (TSS) is caused by staphylococcal and streptococcal superantigens (SAgs) that provoke a swift hyperinflammatory
response typified by a cytokine storm. The precipitous decline in the host’s clinical status and the lack of targeted therapies for
TSS emphasize the need to identify key players of the storm’s initial wave. Using a humanized mouse model of TSS and human
cells, we herein demonstrate that SAgs elicit in vitro and in vivo IL-17A responses within hours. SAg-triggered human IL-17A
production was characterized by remarkably high mRNA stability for this cytokine. A distinct subpopulation of CD4+ effector
memory T (TEM) cells that secrete IL-17A, but not IFN-g, was responsible for early IL-17A production. We found mouse “TEM-
17” cells to be enriched within the intestinal epithelium and among lamina propria lymphocytes. Furthermore, interfering with
IL-17A receptor signaling in human PBMCs attenuated the expression of numerous inflammatory mediators implicated in the
TSS-associated cytokine storm. IL-17A receptor blockade also abrogated the secondary effect of SAg-stimulated PBMCs on
human dermal fibroblasts as judged by C/EBP d expression. Finally, the early IL-17A response to SAgs was pathogenic because
in vivo neutralization of IL-17A in humanized mice ameliorated hepatic and intestinal damage and reduced mortality. Together,
our findings identify CD4+ TEM cells as a key effector of TSS and reveal a novel role for IL-17A in TSS immunopathogenesis. Our
work thus elucidates a pathogenic, as opposed to protective, role for IL-17A during Gram-positive bacterial infections. Accord-
ingly, the IL-17–IL-17R axis may provide an attractive target for the management of SAg-mediated illnesses. The Journal of
Immunology, 2017, 198: 2805–2818.
T
oxic shock syndrome (TSS) is a life-threatening illness
characterized by high-grade fever, diffuse erythematous
rash formation, desquamation, severe hypotension, and
multiorgan dysfunction (1). It is caused by systemic exposure to
bacterial toxins known as superantigens (SAgs), which are se-
creted by Staphylococcus aureus and Streptococcus pyogenes.
TSS can be of menstrual (2) or nonmenstrual (3) origin. The vast
majority of menstrual TSS cases, which are linked to high-
absorbency tampon usage (4), are caused by S. aureus strains
expressing the powerful SAg TSS toxin-1 (TSST-1) (5). In
contrast, nonmenstrual TSS can occur with virtually any S. au-
reus infection and is primarily associated with TSST-1 and
staphylococcal enterotoxin B (SEB) (6). The expression of
streptococcal pyrogenic exotoxin A (SpeA) is also strongly
correlated with streptococcal TSS (7).
SAgs are a unique family of exotoxins that activate a large
proportion of T cells irrespective of their TCR specificity. Cognate
peptide Ags presented in the context of self-MHC by APCs typ-
ically activate one in every 10,000 T cells. In contrast, SAgs si-
multaneously bind MHC class II molecules on APCs outside their
Ag-binding groove (8) and select TCRVb domains on T cells (9).
By doing so, SAgs circumvent conventional modes of Ag pro-
cessing and presentation to induce the activation and proliferation
of up to 50% of all exposed T cells (10). The overwhelming ac-
tivation of T cells by SAgs results in excessive production of in-
flammatory mediators, which is commonly referred to as cytokine
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storm. SAgs directly stimulate the secretion of IL-2, IFN-g, and
lymphotoxin-a from T cells, as well as TNF-a, IL-1b, and IL-6
from APCs (10, 11). Additionally, SAgs initiate secondary in-
flammatory cytokine and chemokine responses from various
nonhematopoietic cell types such as epithelial cells, endothelial
cells, and fibroblasts (12). The massive and uncontrolled release of
these inflammatory mediators has drastic tissue damaging effects
through the activation of the coagulatory cascade, vasodilation,
edema, and vascular leakage (13–16). SAgs also promote the
production of chemokines CXCL8, CCL2, CCL3, and CCL4 (17,
18), resulting in further recruitment of leukocytes to areas of tissue
injury. The net effect of the cytokine storm is a systemic inflam-
matory response syndrome that may culminate in fatal multiorgan
failure.
IL-17A is a potent inducer of systemic inflammation, potenti-
ating the production or activation of inflammatory cytokines (e.g.,
TNF-a, IL-1b, and IL-6), chemokines, matrix metalloproteases,
and transcription factors in both hematopoietic and non-
hematopoietic cell types (19). IL-17A also acts synergistically with
other inflammatory cytokines, including TNF-a, IL-1b, and IFN-g,
to stabilize mRNA transcripts or activate promoter regions of other
inflammatory mediators (20). Although IL-17A is the archetypal
cytokine of the CD4+ Th17 cell lineage (19), it can also be quickly
produced by innate-like T lymphocytes such as gd T cells, invariant
NKT (iNKT) cells, and mucosa-associated invariant T (MAIT) cells
(21, 22). IL-17A is often associated with early and protective host
responses to bacteria, and little is known about its pathogenic po-
tentials during infection. For example, whether exposure to SAgs
elicits an early IL-17A response that may contribute to the cytokine
storm is essentially unexplored.
Identification of early inflammatory mediators of the cytokine
storm and their cellular sources is of utmost importance due to the
rapidity with which TSS may progress to life-threatening disease.
The clinical status of a SAg-exposed individual can deteriorate
to multiorgan failure as early as 8–12 h after the onset of the
symptoms (23), and estimates of TSS mortality range from 4 to
22% (24–26). Also alarmingly, there are currently no available
therapeutics to attenuate the cytokine storm, which drives the
immunopathology of TSS. Therefore, understanding the critical
components of this process may hold the key to designing effec-
tive therapies that reduce TSS-associated morbidity and mortality.
In this investigation, using humanized mice and human PBMCs,
we found and characterized a vigorous IL-17A response that was
detectable within the first few hours of SAg exposure. The kinetics
of this response initially suggested the involvement of innate-like
T cells (21), which we were able to rule out. Instead, we identified
effector memory T (TEM) cells as the major source of mouse and
human IL-17A, which were surprisingly unable to coproduce IFN-
g. IL-17A receptor blockade diminished the expression of several
proinflammatory mediators by SAg-stimulated human PBMCs
and also prevented the secondary upregulation of the tran-
scription factor C/EBP d (CEBPD) in human dermal fibroblasts.
These findings suggested a pathogenic role for IL-17A in TSS,
which we confirmed using a humanized mouse model of the
syndrome. Therefore, to our knowledge, this work defines a pre-
viously unrecognized mechanism of TSS immunopathology that is
dependent upon rapid IL-17A production by a distinct subpopu-
lation of TEM cells.
Materials and Methods
Mice
Adult 6–12 wk-old mice closely matched for age and sex were used in all
experiments. Wild-type C57BL/6 mice were purchased from Charles River
Canada (Saint-Constant, QC). IL-17A–GFP mice that express enhanced
GFP as a marker of IL-17A expression were obtained from The Jackson
Laboratory (Bar Harbor, ME) and bred in a barrier facility at Western
University. HLA-DR4 transgenic (DR4tg) mice, which are devoid of en-
dogenous MHC class II and instead express HLA-DRA-IEa and HLA-
DRB1*0401-IEb on a C57BL/6 background (27), were bred in the same
facility.
To develop a SAg-sensitive IL-17A reporter mouse strain, DR4tg and
IL-17A–GFP mice were crossed. The resultant HLA-DR4 transgenic
IL-17A reporter (D17) mice were bred to homozygosity and confirmed to
express HLA-DR transgenes and the IL-17A–GFP reporter construct but
not IAb. In brief, genomic DNAwas extracted from mouse ear clips using
hot sodium hydroxide and Tris. PCR-amplified products were generated
using Platinum Taq DNA polymerase (Thermo Fisher Scientific, Ottawa,
ON) and primer sets that are listed in Supplemental Table I. Agarose gel
electrophoresis was performed to visualize PCR products.
Wild-type C57BL/6, IL-17A–GFP, DR4tg, and D17 mice were cared for
in the same facility. All animal experiments were conducted in accordance
with an approved institutional animal use protocol (AUP 2010-241) and in
compliance with the Canadian Council on Animal Care guidelines.
Generation of bone marrow chimeras
To obtain donor cells, IL-17A–GFP mice were euthanized by cervical
dislocation, and bone marrow was flushed out of femurs and tibias with
ice-cold PBS. Erythrocytes were lysed by addition of ACK lysis buffer
for 2 min, and resulting cells were filtered through a 70-mm nylon mesh
strainer. Twenty million donor cells were injected i.v. into recipient
DR4tg mice, which were lethally irradiated at 9 Gy using a [137Cs]
gamma irradiator before adoptive transfer. Recipient mice were
maintained on drinking water supplemented with 2 mg/ml neomycin
sulfate (Teknova, Hollister, CA) for 2 wk after irradiation to prevent
infection.
Bacterial toxins
Recombinant staphylococcal and streptococcal SAgs were generated using
an approved institutional biosafety protocol that follows established Public
Health Agency of Canada regulations as described previously (28). Briefly,
SAgs were expressed in BL21 (DE3) Escherichia coli and purified by
nickel column chromatography. As an additional control, an attenuated
mutant of SEB that is impaired in binding to mouse TCR Vb8.2 (29) was
generated by site-directed mutagenesis (30). The mutant SEB carries an
N→A point mutation at position 23 and is referred to as SEBN23A. LPS was
purchased from Sigma-Aldrich (Oakville, ON).
Toxic shock syndrome mouse model and in vivo IL-17A
neutralization
Animals were injected i.p. with indicated amounts of SEB or the
equivalent volume of PBS as a control. They were bled via the saphenous
vein, and serum samples were obtained following centrifugation of blood
at 17,000 3 g for 40 min and analyzed for their cytokine content using
ELISA kits from eBioscience (San Diego, CA). For in vivo IL-17A
neutralization, DR4tg mice were treated with 200-mg i.p. doses of an
anti–IL-17A mAb (clone 17F3; BioXCell, West Lebanon, NH) or a
mouse IgG1 isotype control (clone MOPC-21) 3 h before and 1 h after
they were injected with 100 mg SEB. Mice were monitored every 3 h for
the initial 12 h and every 8 h thereafter for up to 7 d. Weight loss was
assessed at indicated time points, and mice were sacrificed when 20%
weight loss was reached following institutional protocols and Canadian
Council on Animal Care guidelines. For histological analyses, mice were
sacrificed at 48 h post-SEB stimulation. Liver and small intestine were
extracted, fixed in 10% neutral-buffered formalin, embedded in paraffin,
sectioned, and stained with H&E. Sections were scored by a board-
certified veterinary pathologist who was blinded to the experimental
conditions.
Human PBMC isolation and stimulation with SAgs
Peripheral blood was collected in heparinized vacutainers from healthy
volunteers after their written consent was secured and following a protocol
approved by the Western University Research Ethics Board for Health
Sciences Research Involving Human Subjects (HSREB 5545). PBMCs
were isolated by density centrifugation using 50-ml SepMate tubes from
Stemcell Technologies (Vancouver, BC) and low endotoxin (,0.12 en-
dotoxin units per ml) Ficoll-Paque Plus (GE Healthcare Life Sciences)
according to the manufacturer’s instructions. PBMCs were suspended in
RPMI 1640 medium supplemented with 10% heat-inactivated FCS,
0.1 mM MEM nonessential amino acids, 2 mM GlutaMAX-I, 1 mM so-
dium pyruvate, 10 mM HEPES, 100 U/ml penicillin and 100 mg/ml
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streptomycin. PBMCs were stimulated with 100 ng/ml of indicated SAgs
for up to 24 h at 37˚C in polystyrene U-bottom plates at a density of 2 3
106 per well. To block IL-17 receptor A (IL-17RA) prior to SEB stimu-
lation, PBMCs were incubated with 10 mg/ml of an anti–IL-17RA mAb
(clone 133617) or mouse IgG1 isotype control (clone 11711) from R&D
Systems (Minneapolis, MN) for 30 min.
For cytokine assays, culture supernatants were harvested at indicated
time points and analyzed by a bead-based multiplex assay (Eve Technol-
ogies, Calgary, AB). Heat maps were generated using the matrix2png utility
(31). For RNA studies, PBMCs were isolated in RNAlater (Thermo Fisher
Scientific) and RNA was extracted using the Purelink RNA Mini Kit
(Thermo Fisher Scientific). To eliminate contaminating genomic DNA, on-
column Purelink DNase (Invitrogen Canada, Burlington, ON) was used as
per the manufacturer’s instructions. RNA quantity and purity was mea-
sured by a NanoDrop ND-1000 spectrophotometer. RNAwas converted to
cDNA via SuperScript VILO Master Mix (Invitrogen Canada). Quantita-
tive real-time PCR (qPCR) was performed on a StepOnePlus Real-Time
PCR System using TaqMan Gene Expression Assays (Supplemental
Table II) and TaqMan Fast Advanced Master Mix, all from Thermo
Fisher Scientific. qPCR reactions and cycling conditions were set up
according to the manufacturer’s instructions. Fold changes between con-
ditions were calculated by the DD cycle threshold (CT) method. For low-
expressing gene targets that consistently amplified with CT values .37,
CT values were set to 37 for analysis.
As reliable comparisons of gene expression by qPCR require normali-
zation to stably expressed reference genes, we first tested several commonly
used reference genes for changes in SEB-stimulated PBMCs when com-
pared with unstimulated controls. The mean fold changes of TATA-binding
protein and ribosomal protein L13a (RPL13A) were no more or less than
20% (data not shown). TATA-binding protein and/or RPL13A were thus
used as reference genes in our qPCR assays.
To analyze RNA stability/degradation, PBMCs were stimulated with
SEB for 4 h followed by treatment with 5 mg/ml transcriptional inhibitor
actinomycin D (act-D). Cells were harvested at indicated time points, RNA
was extracted and converted to cDNA, and qPCR for target genes was
performed as described above using 18S RNA as the reference gene.
Human PBMC-dermal fibroblast coculturing
Using an approved ethics protocol (HSREB 104888), primary human fi-
broblasts were derived from surgically resected normal skin samples as
previously described (32). Fibroblast cultures were maintained for a
maximum of six passages in DMEM medium containing 10% heat-
inactivated FCS, 2 mM GlutaMAX-I and 13 Antibiotic-Antimycotic
(Thermo Fisher Scientific). Fibroblasts were seeded at a density of 5 3
105 per well in a tissue culture–treated polystyrene flat-bottom plate. Four
million freshly isolated PBMCs were plated into a Nunc Polycarbonate
Membrane Insert (pore size: 0.4 mm), which was placed inside the fibro-
blast culture well. Cocultures were then stimulated with 100 ng/ml SEB.
Eight hours later, the insert was removed and fibroblasts were harvested
and examined by qPCR for their CEBPD expression. In several experi-
ments, anti–IL-17RA mAb or isotype control was added to cocultures at
10 mg/ml 30 min before SEB stimulation.
Isolation and cytofluorimetric analyses of mouse cells
PBS- and SAg-primed mice were sacrificed at indicated time points to
harvest spleen, pooled lymph nodes (cervical, axillary, brachial, mesenteric,
inguinal, and popliteal nodes), liver, lungs, and small intestine. Spleen and
lymph nodes were homogenized using aWheaton Dounce tissue grinder. To
obtain hepatic and lung nonparenchymal mononuclear cells, tissue speci-
mens were pressed through a wire mesh, and the extracted cells were
washed, resuspended in 33.75% low endotoxin Percoll Plus (GE Healthcare
Life Sciences, Mississauga, ON), and centrifuged at 700 3 g for 12 min at
room temperature. Pelleted cells were treated with ACK lysis buffer,
washed, filtered, and resuspended in cold sterile PBS.
Intraepithelial lymphocytes (IELs) and lamina propria lymphocytes
(LPLs) were isolated from the small intestine as described by Sheridan
and Lefrançois (33). Briefly, the small intestine was aseptically removed,
flushed with HBSS containing 5% FCS and 10 mM HEPES, digested at
37˚C with 1 mM dithioerythritol, and filtered through a cell strainer (pore
size: 70 mm) to generate an IEL-containing homogenate. To prepare LPLs,
the remaining intestinal pieces were additionally digested, first in 1.3 mM
EDTA and then in a solution containing 100 U/ml collagenase, and sub-
sequently filtered. IEL- and LPL-containing homogenates were washed,
resuspended in 44% Percoll Plus (GE Healthcare Life Sciences), underlaid
with 67% Percoll Plus, and spun at 600 3 g for 20 min. IELs and LPLs
were harvested by a Pasteur pipette from the buffy coat formed at the
gradient interface, washed, and resuspended in cold PBS.
Freshly isolated mouse cells were incubated with 5 mg/ml of an anti-
mouse CD16/CD32 mAb (clone 2.4G2) to block Fcg receptors and stained
at 4˚C with fluorochrome-conjugated mAbs to cell surface molecules listed
in Supplemental Table II. Corresponding isotype controls were used in
parallel for appropriate gating. A FACSCanto II cytometer (BD Biosci-
ences, Mississauga, ON) was used for data collection. Data were analyzed
by FlowJo software (Tree Star, Ashland, OR).
Surface and intracellular staining of human cells and RNA flow
cytometry
Freshly isolated human PBMCs were stimulated with SAgs for 4 h, unless
otherwise stated, in the presence of 1 mM brefeldin A (Sigma-Aldrich).
Cells were thoroughly washed and stained at 4˚C with fluorochrome-
conjugated mAbs to cell surface molecules (Supplemental Table II). For
intracellular detection of cytokines, the Intracellular Fixation and Per-
meabilization Buffer Set from eBioscience was used. We also employed a
Mouse IL-17A Secretion Assay kit from Miltenyi Biotec (Auburn, CA) to
confirm the secretion of this cytokine. For detection of transcription fac-
tors, the FoxP3 Staining Buffer Set (eBioscience) was used. For RNA
staining, the Prime FlowRNA Assay (eBioscience) was used with probes
designed for the detection of IL-17A, IFN-g and RPL13A signals. Cells
were treated and stained for surface and intracellular molecules
(Supplemental Table II) following the manufacturer’s instructions. Isotype
and/or fluorescence minus one controls were used in parallel for proper
gating. Samples were run on a BD FACSCanto II or a BD LSR II (when
using violet fluorochrome-conjugated mAbs) and analyzed by FlowJo
software (Tree Star).
Statistical analyses
Analyses were carried out using GraphPad Prism 7 software (La Jolla, CA).
The Shapiro–Wilk test was performed to verify the normal distribution of
our data sets. Statistical comparisons were made using parametric Student
t tests, ANOVA with Holm–Sidak post hoc analysis, or log-rank test,
as appropriate and as indicated in the figure legends. Differences with
p # 0.05 were deemed statistically significant.
Results
IL-17A is rapidly produced by CD4+ effector memory T cells in
a humanized mouse model of toxic shock syndrome
SAgs have notoriously poor binding affinity for MHC class II
molecules expressed in certain conventional mouse strains such
as C57BL/6 mice (34). Thus, we investigated the pathogenesis of
TSS in humanized DR4tg mice that allow for high-affinity inter-
actions with SAgs and consequently recapitulate many aspects of
TSS-mediated immunopathology (28, 29, 35–39). Using this
model, we serendipitously found a dramatic serum IL-17A spike
at 2 h post-SEB exposure (Fig. 1A). Given that the role of IL-17A
in TSS is unknown and that IL-17A induces and synergizes with
many inflammatory mediators implicated in the cytokine storm,
we sought to fully characterize this phenomenon. IL-17A was
present in the serum at 2 h but not detectable at 12 or 24 h after i.p.
injection of SEB (Fig. 1A). In contrast, IL-17Awas not detectable
in SEB-injected wild-type C57BL/6 mice (Fig. 1A) and neither
were several other cytokines tested (e.g., IFN-g and IL-4). This
highlights the requirement for human MHC class II molecules in
the optimal activation of T cells by SAgs. The injection of
SEBN23A, a mutant version of SEB with impaired binding to
Vb8.2 TCR (29), into DR4tg mice also resulted in no detectable
IL-17A in the serum (Fig. 1A), indicating that SEB-induced
IL-17A production is highly T cell dependent.
We next tested a panel of bacterial SAgs other than SEB for their
ability to induce IL-17A production in DR4tg mice. These included
TSST-1, staphylococcal enterotoxin A (SEA), SpeA, streptococcal
pyrogenic exotoxin I (SpeI), and streptococcal mitogenic exotoxin
Z (SmeZ). TSST-1 administration did not result in IL-17A ap-
pearance in the serum and neither did SpeI or SmeZ (data not
shown). As such, DR4tg mice do not appear to provide a suitable
model in which to study the role of IL-17A in the context of
TSST-1–mediated TSS or SpeI/SmeZ-triggered host responses. In
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contrast, animals injected with SEA and SpeA had detectable
IL-17A levels in their serum (55 and 286 pg/ml, respectively).
Therefore, the early IL-17A production may not be limited to
staphylococcal TSS, and may also play a role in streptococcal
infections. Of note, LPS, a potent stimulus that activates immune
cells through a different mechanism than SAgs, failed to trigger an
IL-17A response in DR4tg mice (data not shown).
To identify the cellular source of IL-17A, we generated IL-17A–
GFP/DR4tg bone marrow chimeric mice. This system allows for
quantification of IL-17A responses as measured by GFP fluores-
cence in SAg-sensitive, human MHC class II–expressing mice. Three
weeks after the adoptive transfer of bone marrow cells, chimeric
mice were injected with 50 mg SEB and sacrificed 2 h later to
obtain blood, spleen, lymph nodes (cervical, axillary, brachial,
mesenteric, inguinal, and popliteal), liver, lungs, and small intes-
tine. When compared with PBS controls, which showed no de-
tectable IL-17A in serum, SEB-injected chimeric mice produced
substantial amounts of IL-17A after 2 h (Fig. 1B). The greatest
frequency of IL-17A–expressing cells was found among IELs of
the small intestine (Fig. 1C). Notably, the frequencies of IL-17A–
expressing cells did not significantly differ between SEB and PBS
treatment groups (Fig. 1C). However, the mean fluorescence in-
tensity (MFI) of GFP, an indicator of IL-17A production on a per
cell basis, increased upon in vivo SEB exposure in IELs and to a
lesser degree among lung and splenic nonparenchymal
mononuclear cells (Fig. 1C).
Having determined that IL-17A expression was highly upregulated
and most abundant in the IEL compartment after SEB exposure, we
next sought to immunophenotype these rapidly IL-17A–producing
cells. The majority of IL-17A+ cells were defined as CD4+ TEM cells
due to their TCRb+CD4+CD44+CCR72CD62L2CD127+ surface
phenotype (Fig. 1D) (40). Similarly, CD4+ TEM cells constituted
the majority of IL-17A+ cells among IELs of PBS-treated mice
(data not shown).
We previously reported that iNKT cells can be activated by
group II bacterial SAgs, including SEB, leading to a swift cyto-
kine response (29). In addition, a subset of iNKT cells is capable
of producing IL-17A in response to glycolipid Ags (41). There-
fore, it was important to rule in or rule out the participation of
iNKT-17 cells in our model. We found that in vivo stimulation
with SEB gives rise to IL-17A–expressing cells that do not possess
the canonical TCR of iNKT cells as judged by their lack of
FIGURE 1. Rapid IL-17A production by CD4+ TEM cells in a humanized mouse model of TSS. (A) DR4tg mice were injected i.p. with 50 mg SEB,
SEBN23A, or PBS, and bled at indicated time points for serum cytokine measurements. Mean 6 SEM values from two independent experiments are shown
(n = 4). (B–D) IL-17A–GFP/DR4tg chimeric mice were injected i.p. with PBS or 50 mg SEB and sacrificed after 2 h. (B) Serum IL-17A levels in SEB- and
PBS-treated IL-17A–GFP/DR4tg bone marrow chimeric mice were determined by ELISA. Mean values 6 SEM from three independent experiments are
shown (n = 4–5 mice per group). (C) The frequencies of IL-17A–GFP+ cells and the geometric MFI of IL-17 were determined by flow cytometry among
nonparenchymal mononuclear cells (MNCs) obtained from indicated organs of SEB- and PBS-treated mice. Mean values 6 SEM from three independent
experiments are shown (n = 6–7 per group). *p # 0.05, two-tailed Student t test. (D) The phenotype of IL-17A–GFP+ cells among IELs from SEB-treated
mice was determined using fluorochrome-conjugated Abs and tetramers for indicated markers (open black histograms) and isotype controls (filled, gray
histograms). Representative dot plot and histograms from three independent experiments are shown (n = 4–6). N.D., not detectable.
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staining with a-galactosylceramide–loaded CD1d tetramer
(Fig. 1D).
As a confirmatory approach, we generated D17 mice by crossing
DR4tg mice with IL-17A–GFP reporter animals. We found a
pattern similar to that observed in the bone marrow chimeras,
namely increased IL-17A MFI among IELs of SEB-primed D17
mice (Supplemental Fig. 1). IL-17A–producing cells in D17 mice
also similarly exhibited a TEM phenotype. Having an adequate
supply of D17 animals enabled us to additionally investigate the
lamina propria, a site in which IL-17A–secreting T cells are
known to be abundant (42). These experiments revealed
that systemic exposure to SEB raises both the frequency of
IL-17A+CD4+ TEM cells in the lamina propria and the intensity of
IL-17A production by these cells. In fact, the IL-17A response
was stronger in the LPL compartment in comparison with IELs
(Supplemental Fig. 1).
Together, the above findings show that select SAgs induce rapid
IL-17A production by CD4+ TEM cells in a clinically relevant
mouse model of TSS. The IL-17A response by mouse CD4+ TEM
cells requires high-affinity interactions between SAgs and
human MHC, and is most pronounced among intestinal IELs and
LPLs.
SAgs induce a rapid IL-17A response by human PBMCs
in vitro
After we established that SAgs were able to stimulate early IL-17A
production in DR4tg mice, we assessed whether SAgs also elicit
IL-17A responses in human PBMCs. First, PBMCs from healthy
donors were stimulated with SEB or TSST-1 and analyzed for
changes in cytokine mRNA levels by qPCR. Samples from all
donors showed massive IL-17A mRNA upregulation after stimu-
lation by SEB and, to a slightly lesser extent, by TSST-1 (Fig. 2A).
IL-17A mRNAwas highly upregulated at 2 h, reached a maximum
at 4 h, and gradually decreased until 24 h poststimulation
(Fig. 2A). Interestingly, the magnitude and the kinetics of the
IL-17A mRNA response differed considerably when compared
with IFN-g (Fig. 2A, 2B), a prototypic proinflammatory cytokine
that is induced by SAgs in humans (43) and that is considered
pathogenic in mouse models of TSS (44). IL-17A mRNA upreg-
ulation was far greater in magnitude at early time points and began
to decline after 4 h whereas IFN-g mRNA levels steadily in-
creased until 24 h (Fig. 2A, 2B).
To ascertain whether human IL-17A was actively secreted
among other rapidly produced inflammatory mediators (43),
culture supernatants from SAg-stimulated PBMCs were assayed
for cytokines by bead-based multiplexing. Both SEB and
TSST-1 provoked rapid IL-17A and IFN-g responses, which
were detectable as early as 2 h and continued to accumulate
by 24 h (Fig. 2C). The inflammatory cytokines TNF-a and IL-6,
as well as the growth-promoting cytokine IL-2, were also
produced within hours of SAg stimulation (Fig. 2D). Although
the kinetics of cytokine expression was consistent for both
SEB and TSST-1 stimulation, SEB elicited a more robust re-
sponse for most cytokines tested when compared with TSST-1
(Fig. 2C, 2D).
Thus far, our findings revealed an unexpected discordance vis-à-
vis the kinetics of IL-17A expression at mRNA and protein levels;
that is, whereas IL-17A mRNA was rapidly upregulated and
gradually declined after 4 h, IL-17A protein continued to accu-
mulate in the supernatant up to 24 h (Fig. 2A, 2C). This discor-
dance was especially apparent when compared with the IFN-g
expression kinetics that followed a similar pattern for both cyto-
kine mRNA and protein (Fig. 2B, 2C). We hypothesized that
disparities in mRNA stability between IL-17A and IFN-g may
account for the noted differences as more stable mRNA may not
require consistent upregulation for translation into increasing
amounts of protein. Because the degree of IL-17A mRNA stability
in primary human T cells was unknown, we tested our hypothesis
by comparing the half-lives of IL-17A and IFN-g mRNA in SEB-
stimulated PBMC cultures using the transcriptional inhibitor act-D
(45). PBMCs were challenged with SEB for 4 h consistent with
the IL-17A mRNA response peak (Fig. 2A), treated with act-D,
and analyzed for cytokine mRNA expression in the subsequent 8 h
after transcriptional arrest. Intriguingly, whereas IFN-g mRNA
was quickly degraded within the first few hours, IL-17A mRNA
expression remained remarkably stable after the addition of act-D
(Fig. 2E).
These results indicate that SAgs potently activate human PBMCs
to rapidly upregulate IL-17A mRNA and secrete IL-17A protein
within hours. Interestingly, the initial IL-17A mRNA upregulation
is greater in magnitude and yields more stable mRNA in com-
parison with the canonical inflammatory cytokine IFN-g although
both cytokines are quickly secreted in culture.
SAg-exposed human CD4+ effector memory T cells are rapid
and potent producers of IL-17A
As this work provides the initial report of IL-17A secretion in
human PBMCs within the first few hours of SAg exposure, we next
aimed to identify its cellular source. Exposure to either SEB or
TSST-1 resulted in substantial intracellular IL-17A production by
CD3+ T cells within 4 h (Fig. 3A). SEB was significantly more
potent than TSST-1 and caused IL-17A production by 0.182% of
all PBMCs (Fig. 3A). The MFI of IL-17A staining was equivalent
though, indicating that SEB- and TSST-1–stimulated cells syn-
thesized similar amounts of IL-17A on a per cell basis (Fig. 3A).
We also observed that IL-17A+ cells among TSST-1–stimulated
PBMCs showed reduced CD3 expression suggesting partial TCR
downregulation. Lastly, we confirmed that only CD3+ T cells were
actively secreting IL-17A using a cytokine secretion assay in
which IL-17A that is about to be secreted binds to the cell surface
via a bivalent Ab molecule specific for both CD45 and IL-17A
(data not shown).
To immunophenotype IL-17A–producing cells, PBMCs were
challenged with SEB for 4 h and analyzed for a variety of surface
markers and transcription factors by flow cytometry. The vast
majority of IL-17A+ cells expressed high levels of CD4 and
CD45RO, and were CCR72 (Fig. 3B), indicating a surface phe-
notype characteristic of CD4+ TEM cells (46). In line with previous
studies (47–49), IL-17A+ cells also expressed CCR6 and the
transcription factor RORgT (Fig. 3B), which are hallmarks of the
Th17 lineage. Notably, the majority of IL-17A+ cells expressed
the lectin receptor CD161 (Fig. 3B). CD161 is highly expressed
on innate-like T cells including gd T, MAIT, and iNKT cells but
only moderately expressed on Th17 cells (50). Thus, we investi-
gated gd TCR, Va7.2 TCR and iNKT TCR expression to rule
in/out gd T, MAIT, and iNKT cells, respectively (Fig. 3B). These
innate-like T cell subsets, in addition to a small population of
CD8+ T cells, constituted only minor fractions of the overall
IL-17A+ cell population (Fig. 3C). In contrast, CD4+ TEM cells
were the dominant IL-17A–expressing population, which comprised
.75% of IL-17A+ cells (Fig. 3C).
Strikingly, our results revealed thus far that only a small
fraction of PBMCs produced IL-17A protein in response to
SAgs (Fig. 3A) despite the massive upregulation of IL-17A
mRNA observed in bulk PBMCs (Fig. 2A). We initially pos-
tulated that other cell types in addition to CD4+ TEM cells
contributed to the substantial IL-17A mRNA response, but
were not detectable by intracellular IL-17A staining. To
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address this, we used the PrimeFlow RNA assay, a new technol-
ogy that utilizes fluorescent in situ hybridization to enable si-
multaneous detection of cells expressing IL-17A mRNA and
intracellular IL-17A protein by flow cytometry. As expected,
SEB stimulation enhanced the expression of IL-17A mRNA
(Fig. 3D). Moreover, CD4+ TEM cells (CD3
+CD45RO+CCR72)
comprised the majority of IL-17A mRNA+ cells (Fig. 3D), consis-
tent with our intracellular IL-17A protein findings (Fig. 3C).
Notably, a small proportion of IL-17A mRNA-producing CD4+
T cells stained positively for CCR7 (Fig. 3D), indicating that
CD4+ central memory T cells may be a source of IL-17A protein
at later time points. These results indicate that CD4+ TEM cells are
primarily responsible for rapid IL-17A secretion among SAg-
stimulated PBMCs despite their relative rarity.
As multicytokine-producing T cells are reportedly induced by
SEB stimulation at relatively late time points (51), we explored
whether early IL-17A producers would also coexpress IFN-g.
Surprisingly, only a minute subset of IL-17A/IFN-g coexpressors
was detectable following SAg stimulation over a 4 h period, and
the overwhelming majority of cytokine-producing cells exclu-
sively expressed either IL-17A or IFN-g (Fig. 4A). A similar trend
for IL-17A and IFN-g expression was also evident at 24 h post–
SAg stimulation (Fig. 4B). Interestingly, at 4 h post-SEB, CD4+
TEM cells constituted a large proportion of IFN-g
+ cells (Fig. 4C),
similar to IL-17A+ cells observed above. This finding prompted us
to examine whether IL-17A–producing CD4+ TEM cells had the
potential to produce IFN-g mRNA, but were not synthesizing
appreciable amounts of IFN-g protein. We found that only a small
fraction of IL-17A+ cells showed detectable IFN-g mRNA tran-
scripts (Fig. 4D).
Collectively, the above results indicate that SAg-based stimu-
lation of human PBMCs induces a rapid and potent IL-17A re-
sponse that is chiefly mediated by CD4+ TEM cells. Although CD4
+
TEM cells are responsible for substantial early IFN-g production as
well, the IL-17A– and IFN-g–producing subsets were two inde-
pendent populations.
IL-17RA blockade reduces inflammatory gene expression in
staphylococcal enterotoxin B–exposed human PBMCs and
secondarily activated dermal fibroblasts
Many downstream targets of IL-17A signaling are inflamma-
tory cytokines and chemokines (52), which likely augment or
FIGURE 2. SAgs induce rapid IL-17A synthesis by human PBMCs. Human PBMCs were left untreated or stimulated with 100 ng/ml SEB or TSST-1 for
indicated durations. (A) IL-17A or (B) IFN-g mRNA upregulation in SAg-stimulated PBMCs was determined by qPCR. Data are shown as fold change
relative to unstimulated medium control at each time point. (C and D) Cytokine concentrations in the supernatant of SAg-stimulated PBMCs at indicated
time points were determined by bead-based cytokine multiplexing. Mean values 6 SEM from four individual donors are shown. Statistical comparisons
were made by two-way ANOVA (p # 0.0001) with Holm–Sidak post hoc analysis). (E) Human PBMCs were stimulated with SEB for 4 h prior to act-D
treatment. IL-17A and IFN-g mRNA fold changes normalized to time zero (i.e., addition of act-D) were determined by qPCR. Data pooled from three
individual donors are shown. Statistical comparisons were made by two-way ANOVA (p = 0.0072) with Holm–Sidak post hoc analysis. *p # 0.05,
**p # 0.01, ***p # 0.001, ****p # 0.0001.
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perpetuate the overwhelming inflammatory cascade encoun-
tered in TSS. Accordingly, stimulation of human PBMCs
with SEB for 8 h resulted in upregulation of many differ-
ent pro- and anti-inflammatory genes known to be modulated
by IL-17A (Supplemental Table III). Also highly upregu-
lated was the related inflammatory cytokine IL-17F, which sig-
nals through the same IL-17RA/IL-17RC complex (53). Thus,
we sought to evaluate the contribution of IL-17RA signaling
to induction of inflammatory genes in the initiation of the
cytokine storm.
PBMCs were preincubated with a blocking IL-17RA mAb or
isotype control, stimulated with SEB for 8 h, and evaluated for
changes in gene expression by qPCR. IL-17RA blockade resulted
in diminished expression of several key inflammatory cytokines
involved in TSS, including TNF-a, IFN-g, and IL-6 (Fig. 5A).
Additionally, the expression of many chemokines such as CCL5,
FIGURE 3. CD4+ TEM cells are the major source of IL-17A in SAg-stimulated human PBMCs. Human PBMCs were left untreated in medium or
stimulated with 100 ng/ml SEB or TSST-1 for 4 h. (A) IL-17A–producing cells were identified by intracellular cytokine staining and further analyzed by
flow cytometry. Representative dot plots of SAg-stimulated PBMCs are depicted. The percentage of IL-17A–expressing cells and geometric MFI of IL-17A
are shown as mean values 6 SEM for six individual donors. One-way ANOVA (p = 0.0007) with Holm–Sidak post hoc analysis was used (* p # 0.05,
**p # 0.01); n.s., not significant by two-tailed Student t test. (B) IL-17A+ cells were immunophenotyped based on their expression of indi-
cated cell surface and intracellular markers (open red histograms) relative to isotype control (filled, gray histograms). Illustrated data represent
four individual donors displaying similar results. (C) Values represent mean percentages 6 SEM of four individual donors. Subtypes were defined
as: CD4+ TEM (CD4
+CD3+CD45RO+CCR72), CD4+ TCM (CD4
+CD3+CD45RO+CCR7+), gd T (gd TCR+), iNKT (CD3+CD1d tetramer+), MAIT
(CD3+Va7.2 TCR+CD161+), CD8+ T (CD3+CD42CD8+). (D) IL-17A protein and mRNA coexpressing cells were identified using the PrimeFlow
RNA technology and analyzed by flow cytometry. Dot plots are representative of four individual donors. TCM, central memory T cells.
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CCL7, CXCL1, and CXCL6 were highly downregulated. In-
terestingly, the blockade of IL-17RA signaling also resulted in
upregulation of notable anti-inflammatory cytokines IL-4,
TGF-b1, and IL-10 (Fig. 5A). It is noteworthy that in these
experiments, we chose to work with a mAb dose (i.e., 10 mg/ml)
that was previously reported to efficiently block IL-17RA
(54, 55). In a limited number of experiments, we reconfirmed
that this dose could significantly inhibit the upregulation of
CEBPD, a transcription factor linked to acute inflamma-
tory conditions (56), in SEB-exposed PBMCs. In contrast, a
0.1 mg/ml dose of anti–IL-17RAwas completely ineffective, and
a 1 mg/ml dose inhibited CEBPD upregulation only marginally
(data not shown).
In the next series of experiments, we used a human PBMC-
dermal fibroblast coculture system to mimic the secondary effect
of IL-17A signaling in nonhematopoietic cells. To this end, PBMCs
and fibroblasts were cultured in physically separate compartments
prior to SEB stimulation. We found an ∼3-fold increase in the
expression level of CEBPD by dermal fibroblasts that were
cocultured with SEB-primed PBMCs (Fig. 5B). Importantly, this
response was abrogated in the presence of 10 mg/ml anti–IL-17RA
mAb. Also as expected, SEB did not change the expression of
CEBPD in fibroblasts alone, a condition that was used as a control
(Fig. 5B).
Taken together, the above findings strongly suggest that IL-17RA
signaling plays an important proinflammatory role in TSS by in-
creasing the expression of inflammatory mediators that are ex-
pected to contribute to TSS pathogenesis.
IL-17A is pathogenic in an in vivo model of toxic shock
syndrome
Because the cytokine storm drives many symptoms of TSS, at-
tenuation of rapidly produced cytokines that further perpetuate
the inflammatory cascade, such as IL-17A, may be of prime
importance to reduce TSS severity. Furthermore, IL-17A func-
tions through induction of inflammatory mediators in both he-
matopoietic and nonhematopoietic compartments (19). Thus, we
used the DR4tg mouse model, which provides a powerful in vivo
system in which to delineate the role of early IL-17A responses
in TSS. We treated DR4tg mice with an anti–IL-17A mAb 3 h
prior to and 1 h after the administration of SEB and monitored
disease progression. Neutralizing IL-17A at the TSS onset
FIGURE 4. SAg-stimulated IL-17A– and IFN-g–producing cells are two distinct populations. Human PBMCs from healthy volunteers were left un-
treated or stimulated with 100 ng/ml SEB or TSST-1 for 4 h (A, C, and D) or 4 h and 24 h (B). IL-17A– and IFN-g–producing cells were identified by
intracellular cytokine staining and quantified by flow cytometry. Representative dot plots of SAg-stimulated PBMCs and mean percentages 6 SEM from
two to four individual donors are shown. Statistical comparisons were made by one-way ANOVA (p = 0.0255 and p = 0.0224 for SEB and TSST-1
treatment conditions, respectively) with Holm–Sidak post hoc analysis (*p # 0.05). (C) Gated IFN-g–producing cells were immunophenotyped by their
expression of surface markers (open black histograms) relative to isotype control (filled, gray histograms). Data are representative of four individual donors.
(D) IL-17A and IFN-g mRNA coexpressing cells were identified using the PrimeFlow RNA technology and analyzed by flow cytometry. Dot plots are
representative of four individual donors.
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resulted in significantly attenuated weight loss as early as 20 h
after SEB injection (Fig. 6A). Importantly, by 7 d after SEB
injection, 67% of mice that were treated with anti–IL-17A,
compared with only 27% of mice receiving the isotype control,
had survived (Fig. 6B).
Because TSS is characterized by multiorgan dysfunction, we
investigated whether IL-17A neutralization affects SAg-induced
liver and intestinal damage. DR4tg mice receiving SEB and
either an anti–IL-17A mAb or an isotype control were sacrificed
at 48 h post-SEB, and liver and the small intestine were col-
lected for histopathological analyses. SEB induced moderate
periportal inflammation in the livers of both anti–IL-17A– and
isotype control–treated mice (Fig. 6C). However, hepatic stea-
tosis, an early indication of hepatotoxicity (57), was greatly
reduced in anti–IL-17A–treated mice compared with those re-
ceiving the isotype control (Fig. 6C). Furthermore, the small
intestines of mice receiving anti–IL-17A showed less inflam-
mation, epithelial cell damage, and villar blunting compared
with the control cohort (Fig. 6C). As scored by a veterinary
pathologist blinded to the cohorts, the overall TSS pathology for
mice receiving anti–IL-17Awas significantly reduced (Fig. 6D).
Finally, we found a statistically significant decrease in the se-
rum concentration of IL-6, a downstream target of IL-17A
signaling, in anti–IL-17A–treated mice 2 h after SEB adminis-
tration (Fig. 6E).
Collectively, to our knowledge, these results provide the first
report that IL-17A is pathogenic in TSS and that neutralizing IL-17A
ameliorates morbidity, mortality, and tissue damage in a human-
ized mouse model of TSS.
Discussion
The inflammatory response mediated by IL-17A is the result of the
induction and activation of a large network of immune effector
molecules including cytokines, chemokines, acute phase reactants,
tissue remodeling enzymes, antimicrobial peptides, and tran-
scription factors (19). In this way, IL-17A plays a critical role in
the immune response against many different pathogens including
S. aureus (58) and S. pyogenes (59). However, unbalanced or
dysregulated IL-17A responses may also lead to excessive in-
flammation and can therefore be detrimental in several diseased
states (52). In this study, we report a pathogenic role for IL-17A
during infection.
Much of the existing knowledge of TSS pathogenesis has relied
on conventional mouse models (12). However, SAgs exhibit poor
affinity for certain mouse MHC class II molecules (34), and as a
result, many strains of laboratory mice are resistant to TSS.
Sensitizing agents such as D-galactosamine (60) or LPS (61) have
been employed to amplify the effects of SAgs and induce lethality,
but the extent to which these models accurately reflect human TSS
is questionable. For example, D-galactosamine pretreatment leads
FIGURE 5. Blockade of IL-17RA signaling attenuates SEB-induced inflammatory gene expression in human PBMCs and in downstream non-
hematopoietic cells. (A) Human PBMCs were preincubated with 10 mg/ml anti–IL-17RA blocking Ab or isotype control and subsequently stimulated with
100 ng/ml SEB for 8 h. Changes in gene expression were determined by qPCR and represented as log2 (fold change) of the anti–IL-17RA group normalized
to isotype control. Differentially regulated genes were defined as a .10% fold change difference between treatment groups. Fold changes in gene ex-
pression were pooled from three individual donors and are represented as mean values. (B) Human dermal fibroblasts were grown in a flat-bottom plate and
cocultured with human PBMCs that were seeded into a cell culture insert with a permeable membrane. Fibroblasts and PBMCs were in two physically
separate compartments. Cocultures were left untreated or stimulated with 100 ng/ml SEB. Eight hours later, the insert was removed and fibroblasts were
harvested and examined by qPCR for their CEBPD expression. Anti–IL-17RA or isotype control (10 mg/ml each) was added 30 min before SEB stimulation
as indicated. Fold changes in CEBPD gene expression relative to the fibroblast-only condition was calculated for three PBMC samples prepared from three
individual donors. Data are shown as mean 6 SEM (* p # 0.05, two-tailed Student t test).
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to extreme sensitivity to TNF-a–induced apoptosis in hepatocytes
(62), which causes rapid mortality solely due to fulminant hepa-
titis, which does not represent human TSS (63). Here, we inves-
tigated SAg-induced cytokine responses utilizing DR4tg mice that
transgenically express the human MHC class II molecule HLA-
DR4. This allows for high-affinity SAg–MHC class II interactions
resulting in robust activation of T cells and a cytokine storm that,
if left untreated, simulates the potentially catastrophic human TSS
(35–37).
We found that exposure of DR4tg mice to SEB resulted in swift
production of several cytokines in serum, including the inflam-
matory cytokine IL-17A. Cytokines secreted in the early phase of
the cytokine storm are especially important as they trigger endo-
thelial cell damage that compromises vascular homeostasis and
precipitates multiorgan dysfunction (64). Furthermore, rapid se-
cretion of IL-17A not only has inflammatory effects on a wide
variety of cell types throughout the body, it can directly induce
and also synergize with other cytokines that are produced in the
same timeframe. Other studies have found mouse IL-17A secre-
tion in response to SAgs (36, 44, 65). IL-17 is also reportedly
detectable in SEB-stimulated human PBMC cultures, albeit at
relatively late time points (66, 67). Here, we demonstrate that very
early IL-17A is of CD4+ TEM cell origin in mice and in human
PBMC cultures. Furthermore, we show that the rapid induction of
IL-17A, in addition to other cytokines, is dependent on T cell
stimulation because the injection of DR4tg mice with a TCR-
binding mutant form of SEB (SEBN23A) resulted in minimal cy-
tokine secretion. We believe the observed presence of IFN-g, at
moderate levels, after SEBN23A exposure is likely the consequence
of SEB engaging T cells that bear Vb domains other than Vb8.2
(29). Lastly, we extended our investigation to other SAgs and
found that SpeA and SEA could also induce early IL-17A secretion.
FIGURE 6. IL-17A neutralization in a humanized mouse model of TSS reduces morbidity, mortality, and tissue damage. DR4tg mice were injected i.p.
with 200 mg anti–IL-17A neutralizing Ab or isotype control 3 h before and 1 h after receiving 100 mg SEB. (A) Weight loss was monitored every 3 h for
the first 12 h and every 8 h thereafter (n = 15 per group). Two-way ANOVA was used (p = 0.0012) with Holm–Sidak post hoc analysis. *p # 0.05,
**p# 0.01. (B) Survival was monitored up to 7 d after SEB (n = 15 per group). Mice were sacrificed when moribund ($20% weight loss). p = 0.0101, log-rank
test. (C and D) At 48 h after SEB injection, mice were sacrificed for their organs and H&E staining was performed as per standard protocols. Sections
were scored by a veterinary pathologist blinded to the experimental conditions. Histopathology scores represent sum of changes in the liver (periportal
inflammation + microvesicular steatosis) and small intestine (inflammatory cell infiltration + mucosal score [epithelial cell damage + villar blunting])
observed in each section. Parameters received scores from 0 to 3, with 0 = normal, 1 = mild, 2 = moderate, and 3 = severe, and were analysed using two-
tailed Student t test. Stained sections are representative of sham (n = 2), SEB + isotype control (n = 3) and SEB + anti–IL-17A (n = 4) groups. Mean 6
SEM values are shown. (E) Two hours after SEB injection, anti–IL-17A– and isotype control–treated mice (n = 4 per group) were bled and the IL-6
content of serum samples was quantified by ELISA. Mean 6 SEM values are shown. Two-way ANOVA was used (p = 0.05) with Holm–Sidak post hoc
analysis. *p # 0.05, **p # 0.01.
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Therefore, we propose that rapid IL-17A secretion plays a patho-
genic role in both staphylococcal and streptococcal TSS.
To identify the location of IL-17A production in DR4tg mice, we
generated IL-17A–GFP/DR4tg bone marrow chimeric mice as
well as D17 mice in which IL-17A expression can be quantified by
GFP fluorescence. Using these models, we found an increase in
the frequency of IL-17A+ cells and/or the signal intensity of
IL-17A in several tissues, but chiefly among IELs and LPLs from
the small intestine, upon exposure to SEB. Interestingly, although
IL-17A was consistently absent from the serum of PBS-injected
mice, IL-17A–producing cells were readily detectable in these
animals, suggesting that IL-17A is expressed at basal levels in
multiple organs. This observation is in agreement with those of
previous investigations utilizing alternatively generated IL-17A–
GFP mice (68) or IL-17A fate-mapping reporter mice (69) that
showed resting levels of IL-17A among cells of the small intes-
tine. We expand on these findings to implicate CD4+ TEM cells as
the main source of constitutively expressed IL-17A in naive mice.
Nevertheless, it stands to reason that additional sources/locations
of IL-17A may also exist.
Memory T cells are highly enriched in the intestinal mucosa and
their propensity for immediate effector function upon reactivation
(70) puts them in a unique position to be rapidly activated by
SAgs. It has also been suggested that SAgs produced in the in-
testinal tract by food-borne pathogens may cross the gut mucosa
directly (71), placing memory T cells among the first responders
to SAgs. In support of this hypothesis, IL-17A was preferentially
induced in the intestinal epithelial layer by CD4+ TEM cells when
mice were exposed to SEB. Furthermore, a study by Tilahun et al.
(36) demonstrated that most NF-kB expression in SEB-injected
HLA-DR3 mice was induced in the intestines.
The IL-17A response to SEB in mice appears to be translatable
to humans, as PBMCs from healthy human volunteers stimulated
with SAgs in vitro also exhibited rapid IL-17A production. IL-17A
was secreted within hours of SAg exposure along with other in-
flammatory cytokines such as IFN-g, TNF-a, and IL-6. This in-
flammatory profile was most pronounced within the first few hours
of SAg stimulation, with anti-inflammatory cytokines IL-10 and
IL-13 only reaching appreciable levels toward later time points.
This pattern of expression provides additional evidence suggesting
that potential therapies aimed at curbing the overwhelming
cytokine storm in TSS may be most effective early after expo-
sure to SAgs. A study by Krakauer et al. (72) supports this line of
reasoning, where mice surviving TSS showed reduced inflam-
matory cytokine and chemokine levels, though not including IL-
17A, at 8 h post-SEB administration. Furthermore, in a TSS model
utilizing HLA-DR1 mice, lethality was prevented by anti–TNF-a
treatment, which dampened the early but not the later phase of
cytokine release (73). Therefore, it is likely that the early phase of
the cytokine storm is responsible for TSS lethality and that at-
tenuating this response may be a fruitful strategy to prevent
mortality.
Unexpectedly, we observed apparently paradoxical differences
between the kinetics of mRNA upregulation and resulting protein
expression between IL-17A and IFN-g responses in SAg-
stimulated PBMCs. We propose that the variation of kinetics be-
tween the two cytokines may be due, at least in part, to differences
in mRNA stability. However, the mechanisms of posttranscrip-
tional regulation of IL-17A remain ill-defined. In mice, the RNA-
binding protein Hu Ag R positively regulates IL-17A expression
and mRNA stability (74). Conversely, another RNA-binding pro-
tein, tristetraprolin, binds directly to the 39 untranslated region of
IL-17A mRNA to mediate its decay (75). Lastly, the positive
correlation between microRNAs and IL-17A expression in many
diseases other than TSS also suggests that microRNAs may play a
critical role in regulating IL-17A responses (76). Whether RNA-
binding proteins or microRNAs posttranscriptionally regulate
human IL-17A in TSS remains to be elucidated.
Our findings indicate that CD4+ TEM cells predominate in the
early production of both IL-17A and IFN-g in SAg-stimulated
human PBMCs. We also observed that IL-17A and IFN-g re-
sponses by CD4+ TEM cells were mutually exclusive, with only a
small number of cells capable of producing both cytokines si-
multaneously. Thus, we propose that SAgs stimulate pre-existing
and independent lineage-committed CD4+ TEM cell subsets to
rapidly produce IL-17A (TEM-17 cells) and IFN-g (TEM-g cells) in
the initial phases of the cytokine storm. Our results may extend the
traditional paradigm of Th1-, Th2-, and Th17-lineages of activated
effector CD4+ T cells, which proceed to generate the body’s long-
lived pool of TEM cells (77). This notion is supported by recent
reports that human Th17 cells are a terminally differentiated TEM
cell population with a high capacity of self-renewal (78, 79).
The timing and the intensity of SAg stimulation in human
PBMCs also apparently affect the phenotype and cytokine profiles
of activated cells. We found that at 4 h post-SEB stimulation,
IL-17A–producing CD4+ TEM cells exclusively expressed the
Th17-lineage transcription factor RORgT but did not coproduce
IFN-g. In contrast, a recent study by Björkander et al. (80)
demonstrated that 24-h stimulation of human PBMCs with SAgs
induces IL-17A in CD4+ T cells that express the regulatory T cell
transcription factor FOXP3. As FOXP3 has been previously
shown to be upregulated in SAg-stimulated CD4+ T cells over
days of SAg exposure (81), it remains to be seen whether early
IL-17A–producing CD4+ TEM cells may acquire FOXP3 expres-
sion after longer periods of SAg stimulation. In a separate study,
overnight stimulation of human PBMCs with 10 mg/ml SEB (a
100-fold greater concentration of SAg than the dose used in this
study) induced multifunctional CD4+ TEM cells that often coex-
pressed IL-17A and IFN-g (51). Both at 4 and 24 h after SAg
stimulation, we detected only a minute subpopulation of cop-
roducing CD4+ TEM cells. It is possible that the high concentration
of SAg used by McArthur et al. (51) may have been responsible
for the coproducer phenotype. Circulating levels of SAg in pa-
tients’ serum samples range from ∼40 pg/ml in intensive care
units (82) to 50–100 ng/ml in adult burn patients (83), and as high
as 1000 ng/ml in streptococcal TSS patients (84). As such, our
findings utilizing a more conservative concentration of SAg may
represent a more physiologically relevant outcome for SAg stimu-
lation of human PBMCs.
We found that the blockade of IL-17RA signaling in SEB-
stimulated PBMCs attenuated the expression of multiple in-
flammatory genes including IL-6, TNF-a, and IFN-g, which
mediate many toxic effects of TSS (12). Concomitantly, the ex-
pression of anti-inflammatory cytokine genes (IL-10, TGF-b1,
and IL-4) was upregulated by IL-17RA blockade. To our surprise,
CCL20, a chemokine that binds CCR6 to mobilize lymphocytes
and dendritic cells, was also upregulated. Nevertheless, the overall
picture emerging from our IL-17RA blockade experiments strongly
suggests a proinflammatory role for IL-17RA signaling in the con-
text of human PBMC responses to SAgs. Equally important,
IL-17RA blockade in dermal fibroblasts prevented their sec-
ondary response to SEB-exposed PBMCs. Therefore, this ap-
proach may work at multiple levels and may have therapeutic
potentials for TSS. When patients with severe plaque psoriasis
were treated with brodalumab, a mAb against IL-17RA, reduced
expression of inflammatory cytokine transcripts was noted (85).
Our results are also supported by the findings of Crowe et al. (86)
that IL-17RA knockout mice show greatly attenuated cytokine
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storm when infected with influenza virus. In this model, the absence
of IL-17RA signaling decreased lung inflammation, weight loss,
and morbidity.
Remarkably, in vivo neutralization of IL-17A in DR4tg mice at
the onset of TSS led to a significant reduction in weight loss and a
striking increase in survival. We also observed drastic pathological
changes in both the liver and the epithelium of the small intestine in
DR4tg mice exposed to SEB. These mice developed hepatic
microvesicular steatosis, an early toxic change in hepatocytes that
signals serious disease. Characterized by the accumulation of small
lipid vesicles in hepatocytes, microvesicular steatosis is indicative
of impaired mitochondrial b-oxidation of fatty acids and can lead
to multiorgan dysfunction (57). Importantly, microvesicular stea-
tosis occurs in both human TSS (87, 88) and sepsis (89). To our
knowledge, our work is the first description of its reversal in
an animal model of TSS. We also observed considerable epithe-
lial damage and villar blunting in the small intestine of mice
injected with SEB. These pathological changes likely impair in-
testinal function and contribute to the weight loss observed in
SAg-exposed mice. Importantly, in vivo neutralization of IL-17A
in this model markedly attenuated both hepatic steatosis and
damage to the intestinal epithelium. As almost all human TSS
patients show multiorgan dysfunction (90), our results suggest that
IL-17A may be an attractive clinical target to reduce TSS severity.
The key to successful treatment of TSS remains the rapid
identification of the source of infection, appropriate and effective
use of antibiotics, drainage of wounds (or removal of tampon in
menstrual TSS), and supportive care (91). IVIg has also been
shown to improve clinical outcomes in TSS caused by group A
Streptococcus (92). However, there is currently no cure for the
cytokine storm induced by SAgs. Here, we define the rapid pro-
duction of IL-17A by CD4+ TEM cells as a novel mechanism
underlying TSS immunopathology. Our findings suggest that
neutralizing IL-17A function may serve to lessen systemic in-
flammatory cytokine levels and decrease tissue damage in TSS.
Thus, a therapeutic approach targeting the early induction of
multiple inflammatory mediators that are involved in the cyto-
kine storm, including IL-17A, may be effective in averting TSS
mortality.
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Supplemental Table 1: PCR primers/probes used in this study. *Primer was designed to span 
the insertion site of the HLA-DR4 transgenes in the mouse genome (Raffegerst et al: PLoS ONE 2009, 
4(12): e8539), thus enabling discrimination between homozygous and heterozygous transgenic mice. 
Target (reference if applicable) Reactivity Sequence (5’-3’) or Accession #  Source 
HLA-DRA-IEα Forward (27) Human GGGAAGCAGGGGGACTATGAC Sigma-Aldrich 
HLA-DRA-IEα Reverse (27) Human TTAGGGCAATGACTTCGTAGG Sigma-Aldrich 
HLA-DRB1*0401-IEβ Forward (27) Human TGAAAGCGGTGCGTGCTGTTTAA Sigma-Aldrich 
HLA-DRB1*0401-IEβ Reverse (27) Human CACCCGCTCCGTCCCGTTGAA Sigma-Aldrich 
HLA-DR Transgene Insertion Site Forward* Mouse CCATGGACAAGGCAGGGACAAA Sigma-Aldrich 
HLA-DR Transgene Insertion Site Reverse* Mouse CCGTGACCAAAATGCACATTGAA Sigma-Aldrich 
IL-17A-GFP Common Forward (Jackson Primer #15240) Mouse AAGCTGGACCACCACATGA Sigma-Aldrich 
IL-17A-GFP Wildtype Reverse (Jackson Primer #15241) Mouse TGAATCCACATTCCTTGCTG Sigma-Aldrich 
IL-17A-GFP Mutant Reverse (Jackson Primer #11188) Mouse GACATTCAACAGACCTTGCATTC Sigma-Aldrich 
IAβ-neor Forward Mouse GGGAGGAGTACGTGCGCTACGACAG Sigma-Aldrich 
IAβ-neor Reverse Mouse GAGAACCTGCGTGCAATCCATCTTG Sigma-Aldrich 
IAβ Forward Mouse GGCATTTCGTGTACCAGTTCATGG Sigma-Aldrich 
IAβ Reverse Mouse GTCTCCGGCCCCTCGTAGTTGTGT Sigma-Aldrich 
CCL11 Human Hs00237013_m1 Thermo Fischer 
CCL2 Human Hs00234140_m1 Thermo Fischer 
CCL20 Human Hs00355476_m1 Thermo Fischer 
CCL5 Human Hs00982282_m1 Thermo Fischer 
CCL7 Human Hs00171147_m1 Thermo Fischer 
CEBPB Human Hs00270923_s1 Thermo Fischer 
CEBPD Human Hs00270931_s1 Thermo Fischer 
CSF2 Human Hs00929873_m1 Thermo Fischer 
CSF3 Human Hs00738432_g1 Thermo Fischer 
CXCL1 Human Hs00605382_gH Thermo Fischer 
CXCL10 Human Hs01124252_g1 Thermo Fischer 
CXCL11 Human Hs04187682_g1 Thermo Fischer 
CXCL12 Human Hs03676656_mH Thermo Fischer 
CXCL2 Human Hs00601975_m1 Thermo Fischer 
CXCL5 Human Hs01099660_g1 Thermo Fischer 
CXCL6 Human Hs00605742_g1 Thermo Fischer 
CXCL9 Human Hs00171065_m1 Thermo Fischer 
GATA3 Human Hs00231122_m1 Thermo Fischer 
IFNG Human Hs00989291_m1 Thermo Fischer 
IL10 Human Hs00961622_m1 Thermo Fischer 
IL12A Human Hs01073447_m1 Thermo Fischer 
IL12B Human Hs01011518_m1 Thermo Fischer 
IL13 Human Hs00174379_m1 Thermo Fischer 
IL17A Human Hs00174383_m1 Thermo Fischer 
IL17F Human Hs00369400_m1 Thermo Fischer 
IL18 Human Hs01038788_m1 Thermo Fischer 
IL19 Human Hs00604657_m1 Thermo Fischer 
IL1B Human Hs00174097_m1 Thermo Fischer 
IL2 Human Hs00174114_m1 Thermo Fischer 
IL22 Human Hs01574154_m1 Thermo Fischer 
IL23A Human Hs00900828_g1 Thermo Fischer 
IL4 Human Hs00174122_m1 Thermo Fischer 
IL6 Human Hs00985639_m1 Thermo Fischer 
IL8 Human Hs00174103_m1 Thermo Fischer 
LTA Human Hs04188773_g1 Thermo Fischer 
MYD88 Human Hs01573837_g1 Thermo Fischer 
NFKB1 Human Hs00765730_m1 Thermo Fischer 
NFKBIZ Human Hs00230071_m1 Thermo Fischer 
NOS2 Human Hs01075529_m1 Thermo Fischer 
PTGS2 Human Hs00153133_m1 Thermo Fischer 
RORC Human Hs01076112_m1 Thermo Fischer 
RPL13A Human Hs04194366_g1 Thermo Fischer 
TBP Human Hs00427620_m1 Thermo Fischer 
TBX21 Human Hs00203436_m1 Thermo Fischer 
TGFB1 Human Hs00998133_m1 Thermo Fischer 
TNFA Human Hs01113624_g1 Thermo Fischer 
ZBTB16 Human Hs00957433_m1 Thermo Fischer 
!
!
Target Reactivity Host Species Clone/ 
Accession #  
Isotype Fluorochrome Source 
Surface Molecules       
TCRβ Mouse Arm. Hamster H57-597 IgG PE-Cyanine7 eBioscience 
CD4 Mouse Rat GK1.5 IgG2b, κ Alexa Fluor® 700 eBioscience 
CD44 Human/ 
Mouse 
Rat IM7 IgG2b, κ PerCP-Cyanine5.5 eBioscience 
CD62L Mouse Rat MEL-14 IgG2a, κ APC-eFluor® 780 eBioscience 
CCR7 Mouse Rat 4B12 IgG2a, κ APC eBioscience 
CD127 Mouse Rat A7R34 IgG2a, κ PE eBioscience 
iNKT TCR  
(detected by CD1d 
loaded tetramer) 




















Alexa Fluor® 700 
Brilliant Violet™ 510 
eBioscience 
BD Biosciences 
CD8 Human Mouse RPA-T8 IgG1, κ Alexa Fluor® 700 eBioscience 










CD45RO Human Mouse UCHL1 IgG2a, κ APC 
Brilliant Violet™ 785 
eBioscience 
BD Biosciences 
CCR6 Human Mouse G034E3 IgG2b, κ PE BioLegend 












iNKT TCR  
(detected by CD1d 
loaded tetramer) 
Human Human N/A N/A APC NIH Tetramer 
Core Facility 








Cytokines       
IL-17A Human Mouse eBio64-
DEC17 










      
RORγT Human Mouse Q21-559 IgG2a, κ Alexa Fluor® 647 BD Biosciences 
FoxP3 Human Mouse 236A/E7 IgG1, κ APC eBioscience 
Prime-Flow RNA       
IL-17A Human  NM_002190  Type 1 Alexa Fluor® 647 Affymetrix 
IFNγ Human  NM_000619  Type 4 Alexa Fluor® 488 Affymetrix 
RPL13A Human  NM_012423  Type 6 Alexa Fluor® 750 Affymetrix 














Fold Change (SEB relative to 
medium control) 
Donor 1      Donor 2     Donor 3 
IL22 1059.25 355.71 2198.29 
IL17F 737.24 137.67 780.40 
IFNG 304.81 661.94 445.69 
IL17A 253.73 96.47 651.44 
CSF3 583.76 20.88 296.10 
IL6 111.03 6.77 140.41 
IL19 70.28 50.68 115.96 
IL13 45.96 24.00 84.64 
IL2 32.45 58.60 19.38 
IL12B 32.24 2.08 71.23 
CCL20 40.69 2.49 45.23 
CSF2 17.49 26.89 21.14 
IL10 28.65 5.74 29.33 
CXCL9 2.59 37.62 4.11 
CXCL1 10.29 0.74 31.46 
PTGS2 14.72 1.86 12.92 
LTA 5.37 13.70 10.01 
CXCL11 0.51 14.43 1.33 
IL1B 6.39 1.20 5.01 
TNFA 2.26 3.47 6.43 
CXCL5 3.93 0.19 7.15 
CXCL2 4.29 0.56 5.42 
TBX21 3.48 3.80 0.95 
IL8 3.98 0.82 3.03 
IL12A 2.12 3.13 1.63 
IL4 3.13 1.22 2.53 
IL23A 2.13 2.12 2.20 
NFKB1 2.43 1.53 2.02 
CXCL6 2.75 0.08 3.14 
NFKBIZ 2.11 1.29 1.74 
CCL2 1.86 0.39 2.68 
RORC 1.87 2.01 1.00 
CXCL10 0.33 3.50 0.61 
CEBPB 1.11 0.89 0.90 
ZBTB16 0.93 1.05 0.73 
TGFB1 0.70 1.06 0.66 
GATA3 0.50 0.66 0.82 
CCL7 0.55 0.26 1.00 
CCL5 0.68 0.60 0.34 
MYD88 0.58 0.63 0.32 
NOS2 0.58 0.12 0.36 
CEBPD 0.23 0.33 0.32 
CXCL12 0.14 0.27 0.15 
IL18 0.12 0.16 0.06 
Supplemental Table 3: Fold changes in gene expression of SEB-stimulated human PBMCs 




































































































































Supplemental Fig. 1: SEB-primed D17 mice launch a rapid IL-17A response and harbor an 
enriched population of IL-17A-producing CD4+ TEM cells in their small intestine. D17 mice, 
generated by crossing DR4tg and IL-17A-GFP reporter mice, were injected i.p. with 50 µg SEB 
or with PBS. (A) Two hours later, mice were euthanized and the IL-17A content of serum 
samples was measured. N.D.: not detectable. Error bars represent SEM (n=3/group). (B) The 
frequencies of GFP+ cells and the MFI of GFP were determined in non-parenchymal 
mononuclear cells (MNCs) from indicated tissues and among intestinal intraepithelial 
lymphocytes (IELs) and lamina propria lymphocytes (LPLs). * denotes p ≤ 0.05 by two-tailed 
Student’s t-test. (C) GFP+ IELs and LPLs from SEB-injected mice were immunophenotyped 
using fluorochrome-labeled mAbs to indicated markers (open histograms) and isotype controls 
(filled histograms). Depicted data represent findings from 3 mice used in independent 
experiments.              
